Article
Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.
Journal of the National Cancer Institute - 1 May 2017
Taieb Julien, Le Malicot Karine, Shi Qian, Penault-Llorca Frédérique, Bouché Olivier, Tabernero Josep, Mini Enrico, Goldberg Richard M, Folprecht Gunnar, Luc Van Laethem Jean, Sargent Daniel J, Alberts Steven R, Emile Jean Francois, Laurent Puig Pierre, Sinicrope Frank A
Abstract excerpt
Background: The prognostic value of BRAF and KRAS mutations within microsatellite-unstable (MSI) and microsatellite-stable (MSS) subgroups of resected colon carcinoma patients remains controversial. We examined this question in prospectively collected biospecimens from stage III colon cancer with separate analysis of MSI and MSS tumors from patients receiving adjuvant FOLFOX +/- cetuximab in two adjuvant therapy...
Topics
- Adenocarcinoma
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
- Cetuximab
- Chemotherapy, Adjuvant
- Colectomy
- Colonic Neoplasms
